153 related articles for article (PubMed ID: 7551250)
1. Regulatory considerations in vaccine design.
Davenport LW
Pharm Biotechnol; 1995; 6():81-96. PubMed ID: 7551250
[TBL] [Abstract][Full Text] [Related]
2. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
3. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
[TBL] [Abstract][Full Text] [Related]
4. Development and approval of vaccines in the United States.
Botstein P
Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
[TBL] [Abstract][Full Text] [Related]
5. The Regulatory Evaluation of Vaccines for Human Use.
Baylor NW
Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
[TBL] [Abstract][Full Text] [Related]
6. Staphylococcus aureus vaccine conjugate--Nabi: Nabi-StaphVAX, StaphVAX.
Drugs R D; 2003; 4(6):383-5. PubMed ID: 14584973
[TBL] [Abstract][Full Text] [Related]
7. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
Adis International Ltd
Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
[TBL] [Abstract][Full Text] [Related]
8. Regulatory considerations for emergency use of non-USDA licensed vaccines in the United States.
Hill RE; Foley PL; Carr MY; Elsken LA; Gatewood DM; Ludemann LR; Wilbur LA
Dev Biol (Basel); 2003; 114():31-52. PubMed ID: 14677675
[TBL] [Abstract][Full Text] [Related]
9. The costs and effectiveness of large Phase III pre-licensure vaccine clinical trials.
Black S
Expert Rev Vaccines; 2015; 14(12):1543-8. PubMed ID: 26414015
[TBL] [Abstract][Full Text] [Related]
10. FDA regulations for growth factors and related products.
Chapekar MS; Gunter KC
EXS; 1992; 61():471-8. PubMed ID: 1617242
[TBL] [Abstract][Full Text] [Related]
11. Regulatory issues in clinical applications of cytokines and growth factors.
Weiss KD; Siegel JP; Gerrard TL
Prog Growth Factor Res; 1994; 5(2):213-22. PubMed ID: 7919225
[TBL] [Abstract][Full Text] [Related]
12. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
13. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
[TBL] [Abstract][Full Text] [Related]
14. Regulations for vaccines against emerging infections and agrobioterrorism in the United States of America.
Elsken LA; Carr MY; Frana TS; Brake DA; Garland T; Smith K; Foley PL
Rev Sci Tech; 2007 Aug; 26(2):429-41. PubMed ID: 17892163
[TBL] [Abstract][Full Text] [Related]
15. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
16. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues.
Rowland SS; Mayner RL; Barker L
Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026
[TBL] [Abstract][Full Text] [Related]
17. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].
Pfleiderer M; Wichmann O
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841
[TBL] [Abstract][Full Text] [Related]
18. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
19. Trial endpoints for drug approval in oncology: Chemoprevention.
Beitz J
Urology; 2001 Apr; 57(4 Suppl 1):213-5. PubMed ID: 11295630
[TBL] [Abstract][Full Text] [Related]
20. Regulations and procedures in parasite vaccine development.
Schetters TP; Gravendyck M
Parasitology; 2006; 133 Suppl():S189-95. PubMed ID: 17274846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
